Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 1295329, 11 pages
http://dx.doi.org/10.1155/2016/1295329
Review Article

Therapeutic Strategies in HCC: Radiation Modalities

1Nuclear Medicine Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Via P. Pio 1, 85028 Rionero in Vulture, Italy
2Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, 80145 Napoli, Italy
3Oncology Unit, IRCCS Giovanni Paolo II, 70124 Bari, Italy
4CMO Oplonti Medical Centre, 80058 Torre Annunziata, Italy
5Oncology Unit, Università degli Studi di Foggia, 71122 Foggia, Italy

Received 28 February 2016; Revised 24 May 2016; Accepted 5 June 2016

Academic Editor: Tapas Das

Copyright © 2016 R. Gallicchio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Dhanasekaran, A. Limaye, and R. Cabrera, “Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics,” Hepatic Medicine: Evidence and Research, vol. 4, pp. 19–37, 2012. View at Publisher · View at Google Scholar
  2. Surveillance Research Program, National Cancer Institute Fast stats: an interactive tool for access to SEER cancer statistics, November 2011, http://seer.cancer.gov/faststats.
  3. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Okuda, “Hepatocellular carcinoma,” Journal of Hepatology, vol. 32, no. 1, supplement, pp. 225–237, 2000. View at Google Scholar
  5. H. B. El-Serag and A. C. Mason, “Rising incidence of hepatocellular carcinoma in the United States,” The New England Journal of Medicine, vol. 340, no. 10, pp. 745–750, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Deuffic, L. Buffat, T. Poynard, and A. J. Valleron, “Modeling the hepatitis C virus epidemic in France,” Hepatology, vol. 29, no. 5, pp. 1596–1601, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Wallace, D. Preen, G. P. Jeffrey, and L. A. Adams, “The evolving epidemiology of hepatocellular carcinoma: a global perspective,” Expert Review of Gastroenterology and Hepatology, vol. 9, no. 6, pp. 765–779, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. T. P. Hong, P. Gow, M. Fink et al., “Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed,” Hepatology, vol. 63, no. 4, pp. 1205–1212, 2016. View at Publisher · View at Google Scholar
  9. K. Joshi, M. Mendler, R. Gish et al., “Hepatocellular carcinoma surveillance: a national survey of current practices in the USA,” Digestive Diseases and Sciences, vol. 59, no. 12, pp. 3073–3077, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Lencioni, “Chemoembolization in patients with hepatocellular carcinoma,” Liver Cancer, vol. 1, no. 1, pp. 41–50, 2012. View at Publisher · View at Google Scholar
  11. E. Liapi and J.-F. Geschwind, “Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 17, no. 4, pp. 405–406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. W. D. Hsiao, C. Y. Peng, P. H. Chuang et al., “Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study,” BMC Gastroenterology, vol. 16, no. 1, p. 50, 2016. View at Publisher · View at Google Scholar
  13. T. Yamasaki, S. Hamabe, I. Saeki et al., “A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial,” Journal of Gastroenterology, vol. 46, no. 3, pp. 359–366, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Vadot, M. Boulin, B. Guiu et al., “Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma,” Journal of Clinical Pharmacy and Therapeutics, vol. 40, no. 1, pp. 83–90, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. C. H. Yu, J. W. Y. Hui, E. P. Hui et al., “Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization,” Radiology, vol. 270, no. 2, pp. 607–620, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. G. F. Stefanini, P. Amorati, M. Biselli et al., “Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: an Italian experience,” Cancer, vol. 75, no. 10, pp. 2427–2434, 1995. View at Google Scholar · View at Scopus
  17. G. Pelletier, A. Roche, O. Ink et al., “A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma,” Journal of Hepatology, vol. 11, no. 2, pp. 181–184, 1990. View at Publisher · View at Google Scholar · View at Scopus
  18. J. W. Lee, J. K. Oh, Y. A. Chung et al., “Prognostic significance of 18F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy: a multicenter retrospective cohort study,” Journal of Nuclear Medicine, vol. 57, no. 4, pp. 509–516, 2016. View at Publisher · View at Google Scholar
  19. A. Lintia-Gaultier, C. Perret, C. Ansquer, T. Eugène, F. Kraeber-Bodéré, and E. Frampas, “Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma: a 7 years' experience,” Nuclear Medicine Communications, vol. 34, no. 7, pp. 674–681, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Subramanian, T. Das, S. Chakraborty et al., “Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: A Preliminary Animal Study,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 5, pp. 539–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Lambert, K. Bacher, and L. Defreyne, “Rhenium-188 based radiopharmaceuticals for treatment of liver tumours,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 3, pp. 305–310, 2009. View at Google Scholar · View at Scopus
  22. T. Das, S. Chakraborty, H. D. Sarma, M. Venkatesh, and S. Banerjee, “Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer,” Nuclear Medicine Communications, vol. 30, no. 5, pp. 362–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Yu, U. O. Häfeli, M. Sands, and Y. Dong, “90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer,” Applied Radiation and Isotopes, vol. 58, no. 5, pp. 567–573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Ho, J. W. Y. Lau, T. W. T. Leung, J. E. Dancey, and J. Goin, “Intrahepatic 90Y-microspheres for hepatocellular carcinoma,” Journal of Nuclear Medicine, vol. 42, no. 10, pp. 1587–1589, 2001. View at Google Scholar · View at Scopus
  25. Z.-C. Zeng, Z.-Y. Tang, K.-D. Liu, J.-Z. Lu, H. Xie, and Z. Yao, “Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials,” Journal of Cancer Research and Clinical Oncology, vol. 124, no. 5, pp. 275–280, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Liebster and V. Kočandrle, “Exchange labelling of ‘lipiodol’ ultra fluids with lodine-131 and its intra-lymphatic administration with a fistula on the thoracic duct,” Nature, vol. 203, no. 4946, pp. 777–778, 1964. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Raoul, R. Duvauferrier, P. Bourguet et al., “Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled Lipiodol,” Journal de Radiologie, vol. 67, no. 11, pp. 797–801, 1986. View at Google Scholar
  28. D. M. Biederman, J. J. Titano, K. M. Lee et al., “Yttrium-90 glass-based microsphere radioembolization in the treatment of hepatocellular carcinoma secondary to the hepatitis B virus: safety, efficacy, and survival,” Journal of Vascular and Interventional Radiology, vol. 26, no. 11, pp. 1630–1638, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Khajornjiraphan, N. A. Thu, and P. K. Chow, “Yttrium-90 microspheres: a review of its emerging clinical indications,” Liver Cancer, vol. 4, no. 1, pp. 6–15, 2015. View at Publisher · View at Google Scholar
  30. M. Xi, M.-Z. Liu, X.-W. Deng et al., “Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT,” Radiotherapy and Oncology, vol. 84, no. 3, pp. 272–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. P. Beasley, C.-C. Lin, L.-Y. Hwang, and C.-S. Chien, “Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan,” The Lancet, vol. 318, no. 8256, pp. 1129–1133, 1981. View at Publisher · View at Google Scholar · View at Scopus
  32. I. H. McKillop, D. M. Moran, X. Jin, and L. G. Koniaris, “Molecular pathogenesis of hepatocellular carcinoma,” Journal of Surgical Research, vol. 136, no. 1, pp. 125–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Guha and B. D. Kavanagh, “Hepatic radiation toxicity: avoidance and amelioration,” Seminars in Radiation Oncology, vol. 21, no. 4, pp. 256–263, 2011. View at Publisher · View at Google Scholar
  34. C. H. Park, J. H. Suh, H. S. Yoo, J. T. Lee, and D. I. Kim, “Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma therapeutic feasibility study,” Clinical Nuclear Medicine, vol. 11, no. 7, pp. 514–517, 1986. View at Publisher · View at Google Scholar · View at Scopus
  35. F. I. Chou, K. C. Fang, C. Chung et al., “Lipiodol uptake and retention by human hepatoma cells,” Nuclear Medicine and Biology, vol. 22, no. 3, pp. 379–386, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Park, S. I. Choi, H. Kim, H. S. Yoo, and Y. B. Lee, “Distribution of Lipiodol in hepatocellular carcinoma,” Liver, vol. 10, no. 2, pp. 72–78, 1990. View at Google Scholar · View at Scopus
  37. R. E. Hind, M. Loizidou, S. Perring et al., “Biodistribution of Lipiodol following hepatic arterial injection,” British Journal of Surgery, vol. 79, no. 9, pp. 952–954, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Nakajo, H. Kobayashi, K. Shimabukuro et al., “Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer,” Journal of Nuclear Medicine, vol. 29, no. 6, pp. 1066–1077, 1988. View at Google Scholar · View at Scopus
  39. P. Bernal, J.-L. Raoul, J. Stare et al., “International atomic energy agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study,” Seminars in Nuclear Medicine, vol. 38, no. 2, pp. S40–S45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Bernal, J.-L. Raoul, G. Vidmar et al., “Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-Sponsored Multination Study,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 5, pp. 1448–1455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. J. M. Jeong, Y. J. Kim, Y. S. Lee et al., “Lipiodol solution of a lipophilic agent, 188Re-TDD, for the treatment of liver cancer,” Nuclear Medicine and Biology, vol. 28, no. 2, pp. 197–204, 2001. View at Publisher · View at Google Scholar
  42. S.-J. Wang, W.-Y. Lin, W.-Y. Lui, M.-N. Chen, Z.-T. Tsai, and G. Ting, “Hepatic artery injection of yttrium-90-lipiodol: biodistribution in rats with hepatoma,” Journal of Nuclear Medicine, vol. 37, no. 2, pp. 332–335, 1996. View at Google Scholar · View at Scopus
  43. V. Vilgrain, M. Abdel-Rehim, A. Sibert et al., “Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial,” Trials, vol. 15, article 474, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. S. A. Gulec, G. Mesoloras, W. A. Dezarn, P. McNeillie, and A. S. Kennedy, “Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio,” Journal of Translational Medicine, vol. 5, article 15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. W.-Y. Lau, W.-T. Leung, S. Ho et al., “Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study,” British Journal of Cancer, vol. 70, no. 5, pp. 994–999, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Nardelli, E. Castaldi, G. Ortosecco et al., “Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90,” Applied Radiation and Isotopes, vol. 69, no. 1, pp. 52–55, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Storto, A. De Renzo, T. Pellegrino et al., “Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma,” Radiology, vol. 254, no. 1, pp. 245–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Sharma, “Role of external beam radiation therapy in management of hepatocellular carcinoma,” Journal of Clinical and Experimental Hepatology, vol. 4, supplement 3, pp. S122–S125, 2014. View at Publisher · View at Google Scholar
  49. Y. Tanaka, T. Nakazawa, S. Komori et al., “Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes,” Journal of Gastroenterology and Hepatology, vol. 29, no. 2, pp. 352–357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. T. S. Lawrence, M. L. Kessler, and J. M. Robertson, “Conformal high-dose radiation plus intraarterial floxuridine for hepatic cancer,” Oncology, vol. 7, no. 10, pp. 51–57, 1993. View at Google Scholar · View at Scopus
  51. J. M. Robertson, T. S. Lawrence, J. C. Andrews, S. Walker, M. L. Kessler, and W. D. Ensminger, “Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers,” International Journal of Radiation Oncology, Biology, Physics, vol. 37, no. 2, pp. 325–330, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. S. H. Bae, M.-S. Kim, C. K. Cho, K. B. Kim, C. J. Han, and Y. H. Kim, “Feasibility and efficacy of stereotactic ablative radiotherapy for: Barcelona clinic liver cancer-C stage hepatocellular carcinoma,” Journal of Korean Medical Science, vol. 28, no. 2, pp. 213–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Bujold, C. A. Massey, J. J. Kim et al., “Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 31, no. 13, pp. 1631–1639, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. W.-Y. Huang, Y.-M. Jen, M.-S. Lee et al., “Stereotactic body radiation therapy in recurrent hepatocellular carcinoma,” International Journal of Radiation Oncology, Biology, Physics, vol. 84, no. 2, pp. 355–361, 2012. View at Publisher · View at Google Scholar
  55. H. R. Cárdenes, T. R. Price, S. M. Perkins et al., “Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma,” Clinical and Translational Oncology, vol. 12, no. 3, pp. 218–225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Kwon, S. H. Bae, J. Y. Kim et al., “Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer,” BMC Cancer, vol. 10, article 475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. S. Seo, M.-S. Kim, S. Y. Yoo et al., “Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma,” Journal of Surgical Oncology, vol. 102, no. 3, pp. 209–214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. A. W. Katz, S. Chawla, Z. Qu, R. Kashyap, M. T. Milano, and A. F. Hezel, “Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation,” International Journal of Radiation Oncology Biology Physics, vol. 83, no. 3, pp. 895–900, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. J. K. O'Connor, J. Trotter, G. L. Davis, J. Dempster, G. B. Klintmalm, and R. M. Goldstein, “Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation,” Liver Transplantation, vol. 18, no. 8, pp. 949–954, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Al-Kalbani and Y. Kamel, “Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma,” Saudi Journal of Gastroenterology, vol. 14, no. 2, pp. 90–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J.-L. Raoul, D. Guyader, J.-F. Bretagne et al., “Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support,” Journal of Nuclear Medicine, vol. 35, no. 11, pp. 1782–1787, 1994. View at Google Scholar · View at Scopus
  62. W. Y. Lau, T. W. T. Leung, S. K. W. Ho et al., “Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial,” The Lancet, vol. 353, no. 9155, pp. 797–801, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. R. T.-P. Poon, S.-T. Fan, I. O.-L. Ng, C.-M. Lo, C.-L. Liu, and J. Wong, “Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma,” Cancer, vol. 89, no. 3, pp. 500–507, 2000. View at Google Scholar · View at Scopus
  64. T. S. Su, P. Liang, H. Z. Lu et al., “Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients,” Journal of Surgical Oncology, vol. 113, no. 2, pp. 181–187, 2016. View at Publisher · View at Google Scholar
  65. T. Kimura, H. Aikata, S. Takahashi et al., “Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies,” Hepatology Research, vol. 45, no. 4, pp. 378–386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Sanuki, A. Takeda, Y. Oku et al., “Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients,” Acta Oncologica, vol. 53, no. 3, pp. 399–404, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2012. View at Publisher · View at Google Scholar
  68. C. L. Maini, M. G. Scelsa, C. Fiumara et al., “Superselective intra-arterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma,” Clinical Nuclear Medicine, vol. 21, no. 3, pp. 221–226, 1996. View at Publisher · View at Google Scholar · View at Scopus
  69. T. de Baere, P. Taourel, J. M. Tubiana et al., “Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow,” Radiology, vol. 212, no. 3, pp. 665–668, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. C. H. Park, J. H. Suh, H. S. Yoo, J. T. Lee, D. I. Kim, and B. S. Kim, “Treatment of hepatocellular carcinoma (HCC), with radiolabeled lipiodol: A Preliminary Report,” Nuclear Medicine Communications, vol. 8, no. 12, pp. 1075–1087, 1987. View at Publisher · View at Google Scholar · View at Scopus
  71. H. S. Yoo, C. H. Park, J. T. Lee et al., “Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol,” Cancer Chemotherapy and Pharmacology, vol. 33, no. 1, pp. S128–S133, 1994. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Yumoto, K. Jinno, S. Inatsuki et al., “Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution,” Cancer Chemotherapy and Pharmacology, vol. 31, no. 1, pp. S128–S136, 1992. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Heger, S. Bayindir, R. Steckenmesser, and H. Schirmer, “Percutaneous catheter-arteriographies: seldinger technique,” Minnesota Medicine, vol. 53, no. 10, pp. 1093–1097, 1970. View at Google Scholar · View at Scopus
  74. N. Iwata, Y. Seto, and E. Kakishita, “Radiation hepatitis,” Ryōikibetsu Shōkōgun Shirīzu, vol. 8, pp. 588–590, 1995. View at Google Scholar · View at Scopus
  75. J.-F. Bretagne, J.-L. Raoul, P. Bourguet et al., “Hepatic artery injection of I-131-labeled Lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases,” Radiology, vol. 168, no. 2, pp. 547–550, 1988. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Kondo, O. Kimura, and T. Shimosegawa, “Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 21, no. 1, pp. 94–101, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. H. S. Yoo, J. T. Lee, K. W. Kim et al., “Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil,” Cancer, vol. 68, no. 9, pp. 1878–1884, 1991. View at Publisher · View at Google Scholar
  78. H. S. Yoo, C. H. Park, J. H. Suh et al., “Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings,” Cancer Chemotherapy and Pharmacology, vol. 23, no. 1, pp. S54–S58, 1989. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Torizuka, N. Tamaki, T. Inokuma et al., “Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy,” Journal of Nuclear Medicine, vol. 35, no. 12, pp. 1965–1969, 1994. View at Google Scholar · View at Scopus
  80. G. Storto, E. Nicolai, and M. Salvatore, “[18F]FDG-PET-CT for early monitoring of tumor response: when and why,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 2, pp. 167–180, 2009. View at Google Scholar · View at Scopus
  81. F. Maddalena, G. Lettini, R. Gallicchio et al., “Evaluation of glucose uptake in normal and cancer cell lines by positron emission tomography,” Molecular Imaging, vol. 14, no. 8, pp. 490–498, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Lambert and C. Van de Wiele, “Treatment of hepatocellular carcinoma by means of radiopharmaceuticals,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 8, pp. 980–989, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. J. I. Raoul, J. F. Bretagne, J. P. Caucanas et al., “Internal radiation therapy for hepatocellular carcinoma: results of a French multicenter Phase II trial of transarterial injection of iodine 131- labeled Lipiodol,” Cancer, vol. 69, no. 2, pp. 346–352, 1992. View at Google Scholar · View at Scopus
  84. K. Memon, R. J. Lewandowski, A. Riaz, and R. Salem, “Yttrium 90 microspheres for the treatment of hepatocellular carcinoma,” Recent Results in Cancer Research, vol. 190, pp. 207–224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. S. M. Ibrahim, L. Kulik, T. Baker et al., “Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization,” CardioVascular and Interventional Radiology, vol. 35, no. 5, pp. 1094–1101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. Y. Kim do, B. J. Park, Y. H. Kim et al., “Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study,” American Journal of Clinical Oncology, vol. 38, no. 5, pp. 495–501, 2015. View at Publisher · View at Google Scholar
  87. B. Sangro, J. I. Bilbao, J. Boan et al., “Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 3, pp. 792–800, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Edeline, L. Crouzet, B. Campillo-Gimenez et al., “Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 4, pp. 635–643, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Kulik and R. Salem, “Downstaging: looking for answers, generating more questions?” Liver Transplantation, vol. 21, no. 9, pp. 1117–1119, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. W. Y. Lau, S. Ho, T. W. T. Leung et al., “Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres,” International Journal of Radiation Oncology Biology Physics, vol. 40, no. 3, pp. 583–592, 1998. View at Publisher · View at Google Scholar · View at Scopus
  91. W. Park, D. H. Lim, S. W. Paik et al., “Local radiotherapy for patients with unresectable hepatocellular carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 4, pp. 1143–1150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. F. Mornex, N. Girard, C. Beziat et al., “Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies—mature results of the French Phase II RTF-1 trial,” International Journal of Radiation Oncology, Biology, Physics, vol. 66, no. 4, pp. 1152–1158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. J.-L. Raoul, D. Guyader, J.-F. Bretagne et al., “Prospective randomized trial of chemoembolization versus intraarterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma,” Hepatology, vol. 26, no. 5, pp. 1156–1161, 1997. View at Google Scholar · View at Scopus
  94. B. Brans, K. Van Laere, F. Gemmel et al., “Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma,” European Journal of Nuclear Medicine, vol. 29, no. 7, pp. 928–932, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. B. Gray, G. Van Hazel, M. Hope et al., “Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer,” Annals of Oncology, vol. 12, no. 12, pp. 1711–1720, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. M. B. Pitton, R. Kloeckner, C. Ruckes et al., “Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma,” CardioVascular and Interventional Radiology, vol. 38, no. 2, pp. 352–360, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. F. T. Kolligs, J. I. Bilbao, T. Jakobs et al., “Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma,” Liver International, vol. 35, no. 6, pp. 1715–1721, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. E. Ben-Josef, D. Normolle, W. D. Ensminger et al., “Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8739–8747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. P. K. H. Chow, D. Y. H. Poon, M.-W. Khin et al., “Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma,” PLoS ONE, vol. 9, no. 3, Article ID e90909, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Ricke, K. Bulla, F. Kolligs et al., “Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC,” Liver International, vol. 35, no. 2, pp. 620–626, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Pedicini, R. Caivano, B. A. Jereczek-Fossa et al., “Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors,” Theoretical Biology and Medical Modelling, vol. 9, article 23, 2012. View at Publisher · View at Google Scholar
  102. P. Pedicini, A. Nappi, L. Strigari et al., “Correlation between egfr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma,” Radiation Oncology, vol. 7, article 143, 2012. View at Publisher · View at Google Scholar · View at Scopus